SE0103211D0 - New formulations and use thereof - Google Patents

New formulations and use thereof

Info

Publication number
SE0103211D0
SE0103211D0 SE0103211A SE0103211A SE0103211D0 SE 0103211 D0 SE0103211 D0 SE 0103211D0 SE 0103211 A SE0103211 A SE 0103211A SE 0103211 A SE0103211 A SE 0103211A SE 0103211 D0 SE0103211 D0 SE 0103211D0
Authority
SE
Sweden
Prior art keywords
new formulations
composition
nicotine
therapies
manufacturing
Prior art date
Application number
SE0103211A
Other languages
English (en)
Swedish (sv)
Inventor
Nils-Olof Lindberg
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE0103211A priority Critical patent/SE0103211D0/xx
Publication of SE0103211D0 publication Critical patent/SE0103211D0/xx
Priority to CA002461517A priority patent/CA2461517C/en
Priority to ES02799530T priority patent/ES2322847T3/es
Priority to AU2002334522A priority patent/AU2002334522B2/en
Priority to DK02799530T priority patent/DK1429769T3/da
Priority to HK05101072.4A priority patent/HK1068555B/xx
Priority to EP02799530A priority patent/EP1429769B1/de
Priority to CNB028191609A priority patent/CN100500147C/zh
Priority to BR0212857-8A priority patent/BR0212857A/pt
Priority to DE60230883T priority patent/DE60230883D1/de
Priority to RU2004109153/15A priority patent/RU2286153C2/ru
Priority to JP2003530291A priority patent/JP2005504094A/ja
Priority to MXPA04002854A priority patent/MXPA04002854A/es
Priority to KR10-2004-7004471A priority patent/KR20040047866A/ko
Priority to AT02799530T priority patent/ATE420642T1/de
Priority to PCT/SE2002/001611 priority patent/WO2003026655A1/en
Priority to IL16085302A priority patent/IL160853A0/xx
Priority to NZ532527A priority patent/NZ532527A/en
Priority to ARP020103630A priority patent/AR036640A1/es
Priority to ZA2004/02363A priority patent/ZA200402363B/en
Priority to JP2009238604A priority patent/JP2010006845A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0103211A 2001-09-27 2001-09-27 New formulations and use thereof SE0103211D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE0103211A SE0103211D0 (sv) 2001-09-27 2001-09-27 New formulations and use thereof
NZ532527A NZ532527A (en) 2001-09-27 2002-09-10 Nicotine-containing pharmaceutical composition comprising cocoa powder
BR0212857-8A BR0212857A (pt) 2001-09-27 2002-09-10 Formulações e uso destas
RU2004109153/15A RU2286153C2 (ru) 2001-09-27 2002-09-10 Новые препараты и их использование
AU2002334522A AU2002334522B2 (en) 2001-09-27 2002-09-10 New formulations and use thereof
DK02799530T DK1429769T3 (da) 2001-09-27 2002-09-10 Nye formuleringer og anvendelse deraf
HK05101072.4A HK1068555B (en) 2001-09-27 2002-09-10 New formulations and use thereof
EP02799530A EP1429769B1 (de) 2001-09-27 2002-09-10 Neue formulierungen und ihre verwendung
CNB028191609A CN100500147C (zh) 2001-09-27 2002-09-10 新制剂及其用途
CA002461517A CA2461517C (en) 2001-09-27 2002-09-10 Nicotine formulations comprising cocoa and use thereof
DE60230883T DE60230883D1 (de) 2001-09-27 2002-09-10 Neue formulierungen und ihre verwendung
ES02799530T ES2322847T3 (es) 2001-09-27 2002-09-10 Formulaciones nuevas y uso de las mismas.
JP2003530291A JP2005504094A (ja) 2001-09-27 2002-09-10 新規の配合物及びその使用
MXPA04002854A MXPA04002854A (es) 2001-09-27 2002-09-10 Nuevas formulaciones y uso de las mismas.
KR10-2004-7004471A KR20040047866A (ko) 2001-09-27 2002-09-10 신규한 제제 및 그의 용도
AT02799530T ATE420642T1 (de) 2001-09-27 2002-09-10 Neue formulierungen und ihre verwendung
PCT/SE2002/001611 WO2003026655A1 (en) 2001-09-27 2002-09-10 New formulations and use thereof
IL16085302A IL160853A0 (en) 2001-09-27 2002-09-10 Nicotine containing formulations and use thereof
ARP020103630A AR036640A1 (es) 2001-09-27 2002-09-26 Formulaciones y uso de las mismas
ZA2004/02363A ZA200402363B (en) 2001-09-27 2004-03-25 New formulations and use thereof
JP2009238604A JP2010006845A (ja) 2001-09-27 2009-10-15 新規の配合物及びその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103211A SE0103211D0 (sv) 2001-09-27 2001-09-27 New formulations and use thereof

Publications (1)

Publication Number Publication Date
SE0103211D0 true SE0103211D0 (sv) 2001-09-27

Family

ID=20285457

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103211A SE0103211D0 (sv) 2001-09-27 2001-09-27 New formulations and use thereof

Country Status (19)

Country Link
EP (1) EP1429769B1 (de)
JP (2) JP2005504094A (de)
KR (1) KR20040047866A (de)
CN (1) CN100500147C (de)
AR (1) AR036640A1 (de)
AT (1) ATE420642T1 (de)
AU (1) AU2002334522B2 (de)
BR (1) BR0212857A (de)
CA (1) CA2461517C (de)
DE (1) DE60230883D1 (de)
DK (1) DK1429769T3 (de)
ES (1) ES2322847T3 (de)
IL (1) IL160853A0 (de)
MX (1) MXPA04002854A (de)
NZ (1) NZ532527A (de)
RU (1) RU2286153C2 (de)
SE (1) SE0103211D0 (de)
WO (1) WO2003026655A1 (de)
ZA (1) ZA200402363B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103210D0 (sv) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof
SE0103211D0 (sv) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof
US7767698B2 (en) 2002-06-03 2010-08-03 Mcneil Ab Formulation and use thereof
SE0300831D0 (sv) * 2003-03-26 2003-03-26 Pharmacia Ab New formulations and use therof
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
BRPI0415741B1 (pt) 2003-11-07 2013-07-23 composições de tabaco e métodos de fabricação de uma composição de tabaco
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1977746B8 (de) * 2007-04-02 2014-09-24 Parkinson's Institute Verfahren und Zusammensetzung zur Verringerung der Nebenwirkungen von therapeutischen Behandlungen
GB2468424B (en) * 2007-04-02 2011-11-09 Parkinson S Inst Methods and compositions for reduction of side effects of therapeutic treatments
TW201444815A (zh) 2007-06-13 2014-12-01 大塚製藥股份有限公司 含雌馬酚（ｅｑｕｏｌ）之萃取物、其製造方法、雌馬酚萃取方法及含雌馬酚之食品（二）
WO2009070978A1 (fr) * 2007-11-22 2009-06-11 Yu He Libération rapide dans la cavité buccale des produits de santé et procédé de préparation associé
CN101439053A (zh) * 2007-11-22 2009-05-27 何煜 一种中药口腔速释制剂及其制造方法
US9204667B2 (en) * 2010-12-01 2015-12-08 R.J. Reynolds Tobacco Company Smokeless tobacco pastille and injection molding process for forming smokeless tobacco products
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
CN104338133A (zh) * 2013-07-24 2015-02-11 陆媛 防治口鼻咽喉上呼吸道感染的嚼服药物组合物及其应用
WO2015013679A1 (en) * 2013-07-26 2015-01-29 Gregory Aharonian Uses of coca leaf or valerian root to reduce bitterness in foods containing unsweetened cacao
JP2015084771A (ja) * 2013-09-24 2015-05-07 アサヒ飲料株式会社 容器詰め果汁含有飲料、容器詰め果汁含有飲料の製造方法及び異風味抑制剤
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
JP2021530431A (ja) * 2018-04-16 2021-11-11 ポビバ コーポレーションPoviva Corp. ニコチン化合物を含ませた組成物及び其れ等の使用の方法
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
DK202430540A1 (en) * 2024-09-12 2026-03-26 Fertin Pharma As Orally disintegrating nicotine tablet with reduced sweetener content

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB728759A (en) * 1951-08-25 1955-04-27 Pfizer & Co C Improvements in or relating to coated antibiotics
GB8317576D0 (en) * 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
GB8615676D0 (en) * 1986-06-26 1986-07-30 Stoppers Co Ltd Nicotine containing lozenge
CA1273878A (en) * 1987-01-15 1990-09-11 Richard Philip Moody Nicotine-containing preparation for transdermal administration
DK615689A (da) * 1989-11-07 1991-05-08 Anders Dam Rygesupplement eller rygeerstatningsprodukt
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
FR2717387B1 (fr) * 1994-03-17 1996-10-18 Hi Pharmtech Procédé de fabrication de comprimés à croquer à base de troxérutine, de carbonate de calcium, de phosphate de calcium, d'aspartate d'arginine, de glutamate d'arginine d'amoxicilline.
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
GB9702392D0 (en) * 1997-02-06 1997-03-26 Boots Co Plc Therapeutic agents
SE9803986D0 (sv) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
SE0103211D0 (sv) * 2001-09-27 2001-09-27 Pharmacia Ab New formulations and use thereof

Also Published As

Publication number Publication date
ATE420642T1 (de) 2009-01-15
AR036640A1 (es) 2004-09-22
HK1068555A1 (zh) 2005-04-29
RU2004109153A (ru) 2005-04-20
ZA200402363B (en) 2005-03-30
ES2322847T3 (es) 2009-06-30
RU2286153C2 (ru) 2006-10-27
EP1429769A1 (de) 2004-06-23
WO2003026655A1 (en) 2003-04-03
EP1429769B1 (de) 2009-01-14
KR20040047866A (ko) 2004-06-05
JP2010006845A (ja) 2010-01-14
CN1561214A (zh) 2005-01-05
JP2005504094A (ja) 2005-02-10
MXPA04002854A (es) 2005-06-06
CA2461517C (en) 2008-09-02
DK1429769T3 (da) 2009-05-11
DE60230883D1 (de) 2009-03-05
BR0212857A (pt) 2004-10-13
AU2002334522B2 (en) 2007-05-24
IL160853A0 (en) 2004-08-31
CA2461517A1 (en) 2003-04-03
CN100500147C (zh) 2009-06-17
NZ532527A (en) 2005-09-30

Similar Documents

Publication Publication Date Title
CA2461517A1 (en) Nicotine formulations comprising cocoa and use thereof
DE60202477D1 (de) Vorrichtung zur verabreichung einer substanz
PT1412384E (pt) Formulação estável de glp-1 modificado
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
TW200510375A (en) New compounds
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
IL164108A (en) Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders
IL153297A0 (en) Compounds and compositions for delivering active agents
SE9901875D0 (sv) Novel compounds
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
WO2002047668A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und ciclesonide
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
TW200503782A (en) New formulations and use thereof
WO2003087049A3 (de) Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum
TW200512207A (en) Substituted 3-(2, 5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases
SE0103210D0 (sv) New formulations and use thereof
SE0200657D0 (sv) Novel Formulation
MXPA05000978A (es) Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas.
DE60311665D1 (de) Pharmazeutische zusammensetzungen
HUP0500958A3 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them